New research has revealed that gliomas in neurofibromatosis type 1 patients may respond well to immunotherapy due to their genetic vulnerabilities.
Browsing: Taxonomy > Immunotherapy
The KEYNOTE-040 trial has shown that a novel immunotherapy treatment can extend the lives of some patients with advanced head and neck cancer for up to 3 years or more.
Find out about T-VEC, which was the first oncolytic virotherapy that was approved by the FDA as well as the CheckMate 141 trial.
This past week, the Nobel Prizes in Physiology or Medicine was awarded to research scientists James Allison (University of Texas…
Tasuku Honjo and James P Allison have been awarded the 2018 Nobel Prize in Physiology or Medicine for their discovery of cancer therapy by inhibition of negative immune regulation.
Researchers have demonstrated for the first time that immune cells in the urine of bladder cancer patients accurately reflect those in the tumor environment.
Among prostate cancer patients, those with DNA mismatch repair mutations have particularly aggressive progression and reduced survivability. Though these tumors are more resistant to traditional treatment methods, a recent study has shown that they may be more susceptible to immunotherapy.
The ground breaking CAR-T therapy – Kymriah® – is set to become the first personalized cancer therapy available on the NHS.
Researchers have demonstrated that artificial intelligence can provide a predictive score for the efficacy of immunotherapy in cancer patients.
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.